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Abstract. Blacks/African Americans have been reported to be∼2–4 times more likely to develop clinical Alzheimer’s disease
(AD) compared to Whites. Unfortunately, study design challenges (e.g., recruitment bias), racism, mistrust of healthcare
providers and biomedical researchers, confounders related to socioeconomic status, and other sources of bias are often
ignored when interpreting differences in human subjects categorized by race. Failure to account for these factors can lead
to misinterpretation of results, reification of race as biology, discrimination, and missed or delayed diagnoses. Here we
provide a selected historical background, discuss challenges, present opportunities, and suggest considerations for studying
health outcomes among racial/ethnic groups. We encourage neuroscientists to consider shifting away from using biologic
determination to interpret data, and work instead toward a paradigm of incorporating both biological and socio-environmental
factors known to affect health outcomes with the goal of understanding and improving dementia treatments for Blacks/African
Americans and other underserved populations.
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INTRODUCTION
Studying dementia across racial/ethnic popula-
tions is a controversial but important area of research.
Findings from clinical studies have indicated that
Blacks/African Americans are more likely to develop
Alzheimer’s disease (AD, a major cause of dementia)
in comparison to Caucasians (hereafter referred to as
Whites) [1–3]. In studies that include autopsy confir-
mation, the outcomes are less clear: Blacks/African
Americans may develop more AD and/or mixed
pathologies than Whites [4, 5]; however, other stud-
ies found either no AD pathological differences
between Blacks/African Americans and Whites [6–9]
or higher burden of AD pathology in Whites in
comparison to Blacks/African Americans [10]. Rea-
sons for differences in the studies’ outcomes may
be attributable partly to residual confounding related
to a failure to take into account historical, cultural,
political, sociological, and psychological factors that
contribute to health outcomes. Perhaps most impor-
tantly, clinical research participation in historically
marginalized groups (e.g., Blacks/African Ameri-
cans) has influenced reported research outcomes.
With this commentary, it is our intention to help
focus attention on achieving one of the National Insti-
tutes of Health (NIH) and the U.S. Department of
Health & Human Services (USDHS) objectives to
“increase the availability and quality of data col-
lected and reported on racial and ethnic minority
populations” [11]. We outline a selected historical
account of the relationship between Blacks/African
Americans, medicine, and research, focusing on chal-
lenges and relevant factors that impact Black/African
American participation in research. We conclude with
considerations and topical questions for neuroscien-
tists with a focus on research related to dementia in
Blacks/African Americans.
Note on terminology: Hereafter, we apply racial
categorical terminologies described in the 1997
“Revisions to the Standards for the Classification
of Federal Data on Race and Ethnicity” issued by
Office of Management and Budget’s (OMB): “Black/
African American” and “White.” For complete defi-
nitions, see reference [12].
The contemporary consequences of historical
medical mistreatment of Blacks/African
Americans
There is a long history of horrific biomedical exper-
imentation on Blacks/African Americans and the
effects linger to this day. A selection of examples
are discussed here for three reasons: 1) to convey
that late 19th century/early 20th century scientists
designed abusive studies which grossly violate the
concept of primum non nocere (“first, do no harm”);
2) to provide examples on the dangers of misinterpret-
ing differences between individuals within different
racial/ethnic groups; and 3) to demonstrate how the
history of racism in the medical sciences and society
affect current Black/African American participation
in clinical research. Nineteenth and early 20th century
scientists developed analytical methodologies that
lay the foundation for how we conduct 21st century
science. Therefore, the history highlights method-
ological pitfalls that are topical and highly relevant
to the contemporary setting.
Before the U.S. Civil War, African slaves were
regularly used as involuntary test subjects in biomed-
ical experimentations [13, 14], and these practices
were supported by law [15]. Often, slave masters
offered their slaves to physicians either for biomedi-
cal experimentation or because the slaves were either
too sick or old, or in exchange for medical treat-
ment payment [13]. In addition, some physicians
would buy and raise slaves in order to fill their
studies with human test subjects [13, 15]. The prac-
tice of collecting slaves as research subjects was
not an anomaly but a standard practice due to the
mainstreaming of racism in much of American soci-
ety, including science. Some writers use the term
‘scientific racism’ to describe this perversion of sci-
entific and historical factors to maintain existing
social hierarchies based on race [16, 17]. For exam-
ple, it was believed that Blacks/African Americans
could endure more painful stimuli, extreme heat,
and were more prone to fevers, syphilis, tubercu-
losis, and tetanus than White individuals [15, 18].
These 19th and early 20th century scientists used
this framework of racism to design flawed experi-
ments that yielded results that further inappropriately
justified their use of slaves in biomedical experi-
mentation. For example, lacking a rational scientific
reason, Dr. Walter F. Jones repeatedly poured boil-
ing water on naked slaves in four-hour intervals to
see if it cured typhoid pneumonia [15, 19, 20]. Dr.
John M. B. Haden stripped blood vessels from the
limbs of a Black/African American male in order to
study vascular morphology [15, 21]. Dr. James M.
Sims, “the father of gynecology,” performed painful
experimental gynecological surgery on female slaves
without using anesthesia in order to improve his sur-
gical techniques [13, 22, 23]. Dr. T.S. Hopkins gave
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nitric acid solutions to slaves in order to test its
effects on treating asthma [13, 15]. Thomas Jefferson
inoculated over 200 slaves with the cowpox vac-
cine in order to test its efficacy against smallpox
[15, 20]. These examples demonstrate how racialized
science became part of the justification and prac-
tice of human experimentation on Blacks/African
Americans [16].
After the abolition of slavery in the U.S., physi-
cians and scientists continued to abuse Blacks/
African Americans while conducting unethical
biomedical experimentation. One of the most well-
known unethical studies was the Tuskegee Syphilis
Trials from 1932–1972 [15, 20, 24, 25]. Funded
by the USDHHS, scientists withheld treatment from
400 Black/African American men in order to study
the progression of syphilis. One goal of the study was
to test the long-standing belief that venereal diseases
manifested differently in Black/African American
individuals compared to White individuals [15, 20,
24, 25]. In an article published in 1937, Dr. Mark
Boyd describes conducting an experiment where he
infected 470 syphilitic Black/African American indi-
viduals with a deadly falciparum strain in order
to test new treatments for neurosyphilis [15, 26].
Although some of the individuals died as a direct
result from his procedure, he still continued to infect
other Black/African American individuals [15, 26].
In 1952, Chester M. Southam of Sloan-Kettering
Institute injected at least 396 inmates at the Ohio
State Prison (more than 45% of the subjects were
Black/African American) with live human cancer
cells [15, 27]. From 1962–1966, Dr. Allen Horn-
blum conducted over 153 experiments using mostly
Black/African American men from the Philadel-
phia’s Holmesburg Prison system [15, 28]. Hornblum
was paid by pharmaceutical and cosmetic com-
panies to test cosmetics, powders, and shampoos,
some of which caused baldness, scarring, and per-
manent skin and nail injury in the prisoners [15,
28]. In 1978, without parental consent, physicians
from the Medical College of Virginia injected 1,230
children (37% were Black/African American chil-
dren, 4 times their population representation during
that period) with radioactive substances [15]. From
1993–1995, scientists from the Kennedy Krieger
Institute (KKI) conducted research investigating low-
cost partial lead abatement procedures in children
living in Baltimore’s public housing facilities [29].
As a result, families sued the KKI stating that
they were not fully informed of the risks of their
children’s participation in the study [29]. In sum-
mary, the physicians and scientists in these studies
performed horrific and sometimes deadly experi-
ments on many Black/African American individuals
without regard for their informed consent or well-
being. This is by no means an exhaustive list of
all the unethical biomedical studies performed on
Blacks/African Americans. The historic and pre-
sumed (by many) present practice of unethical
research on Black/African American individuals con-
stitute a primary reason for the distrust of physicians
and scientists within the Black/African American
community—a direct factor limiting their desire
to participate in biomedical research [24, 30–33],
among other factors. In a systematic review of barri-
ers and facilitators to minority research participation,
George et al. found that 77% (n = 34) of the arti-
cles included in their analyses stated that “mistrust of
the medical system” was a barrier for Black/African
American participation in clinical human studies
[33]. Using a national survey completed by 527
Blacks/African Americans and 382 Whites, Corbie-
Smith et al. reported that Blacks/African Americans,
compared to Whites, were more likely to believe that
they would be used as guinea pigs in biomedical
experimentation without their consent (79.2% versus
51.9%, p < 0.01) [30].
Due to Blacks’/African Americans’ mistrust of
the biomedical community and other factors (e.g.,
racism, religious beliefs, access to medical care),
they are also less likely to donate their biospec-
imens (e.g., blood) or agree to an autopsy for
research [34–39]. Using a national survey completed
by 249 Blacks/African Americans and 492 Whites
from six U.S. cities, Minniefield et al. found that
Blacks/African Americans had a lower total preva-
lence (63%) of support for organ donation compared
to Whites (90%) [39]. More specific to brain dona-
tion for clinical research, using a survey completed
by 49 Blacks/African Americans and 184 Whites
recruited from an AD registry, Jefferson et al. found
that only 49% of Blacks/African Americans com-
pared to 75% of Whites would agree to brain donation
for research (p > 0.001) [37]. Therefore, in order
to increase Blacks/African American participation,
several U.S. Alzheimer’s Disease Centers (ADCs)
responsible for conducting large-scale longitudinal
human studies focused on dementia in elderly indi-
viduals, do not require Blacks/African Americans to
agree to a brain donation upon enrolling into research
studies, while they do require brain donation for
White participants [40]. This recruitment strategy
can potentially lead to increased autopsy-recruitment
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bias and limited generalizability of results. Such
limitations must be adequately accounted for in
analyses and discussed in research articles when
reporting on Blacks/African Americans in ADC
studies.
CHALLENGES IN STUDYING
AND COMPARING CLINICAL-
NEUROPATHOLOGICAL VARIABLES
BETWEEN BLACK/AFRICAN
AMERICANS AND WHITE AMERICANS
In studying the epidemiology of AD and related
diseases while comparing Blacks/African Americans
to Whites, some pitfalls become apparent: 1) lack of
clarity in the operationalization and/or definition of
race, 2) using race as a proxy for genetics, 3) fail-
ure to account for socio-environmental factors (e.g.,
socioeconomic status, access to healthcare), 4) lack
of autopsy validation, and 5) lack of racial/ethnic and
scientific diversity within research teams.
Using race as a variable in biomedical research
is deceptively challenging, due to its vague defini-
tion, social implications, confounding factors, and
potential for misinterpretation of results [41–43]. The
historically evolving definitions of race (skin color,
along with other physical and “ancestral” factors)
have been discussed by Tishkoff et al., Guthrie, and
Williams et al. [44–46]. Within these definitions, it is
important to note the lack of clarity and consensus-
based implications of the term “race” across various
fields of study [41, 45, 47–49]. It has been noted
that historic viewpoints of the biological construct of
race were not grounded in firm scientific discovery
[45, 49, 50] but based on early 19th/20th cen-
tury racist scientific studies, such as comparing
“physiognomy” of Blacks/African Americans and
Whites [15, 41, 45, 46, 51]. It has now been well-
established that race is, in many senses, a social
construct with categories that change over time due to
social policy, cultural beliefs, and political practices
[47–49]. Therefore, some scholars have suggested
that race/ethnicity not be used as a proxy for socio-
environmental factors, but deconstructed into specific
indictors such as region, language, education, eco-
nomic level, and access to health care [52–54].
An important consideration is the relationship
between race and genetics: variability in genomic
phenomena between racial categories and variation
of ancestral genetic markers within and between
racial groups. Sometimes, there can be more genetic
variation among individuals within the same racial
category than between individuals from different
racial categories [55–57]. Using genetic information
on 5,269 Blacks/African Americans, 8,663 Latinos,
and 148,780 Whites from 23 and Me, Bryc et al. [56]
found that Blacks/African Americans living in dif-
ferent parts of the U.S. showed varying frequencies
of genetic “African” ancestral markers. For example,
a self-described “Black/African-American” living
in the South had more “African” ancestral gene
markers compared to “Blacks/African-Americans”
living in the Northeast, Midwest, the Pacific
Northwest, and California [56]. Moreover, self-
identified “Blacks/African-Americans” living in the
West and Southwest had higher frequencies of
“Native American” ancestral gene markers com-
pared to “Blacks/African-Americans” living in other
parts of the U.S. [56]. Thus, according to this
sample, self-identified “Black/African-Americans”
across the U.S. have varying proportions of “African”
ancestral genetic markers [56]. Similar results of
varying “African” ancestral genetic markers in
Blacks/African Americans were found by Sinha et
al. in a cohort consisting of individuals living in
Cleveland, OH [58]. In a 2003 New England Jour-
nal of Medicine article, Cooper et al. explains that
Blacks/African Americans are assumed to be pre-
disposed genetically to disease gene(s) even when
genetic evidence is lacking, and the over-emphasis of
genetics may support biases that further marginalize
Blacks/African Americans [59].
Evidence from these papers indicates that race
is not a dependable proxy for genetics given the
sample-to-sample variation of ancestral genetic back-
grounds among individuals within the same category
operationalized by self-identification. Further, since
many confounders (see below) apply, there is a
serious risk of errantly associating a relatively “race-
specific” genetic marker with a trait, when it actually
is attributable to a regional or social factor. Continu-
ing to use race as a proxy for genetic factors has the
potential for detrimental political, social, and med-
ical outcomes as a result of the over-simplification
of results based on genetics, including medi-
cal stigmatization, racialization, genetic determin-
ism, discrimination, and missed/delayed diagnoses
[42, 44, 48, 59, 60].
To discuss race-related differences, environmen-
tal variables should be collected and accounted for
before attributing and discussing genetics as a causal
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factor. There are many sources of bias and con-
founders [61]. Associations with race are potentially
confounded by socioeconomic status (SES) variables
including income level, education, and access to med-
ical care [61–63]. In 2012, the U.S. Census Bureau
reported that the median income for Black/African
American households was $33,321 compared to
$57,009 for White households [64]. In the same 2012
report, the percentage of Black/African American
individuals living in poverty was 27.2% compared
to 9.7% of White individuals [64]. In 2015, the
Centers for Disease Control and Prevention (CDC)
conducted a health interview survey that showed
that 14.5% of Black/African American individuals
were uninsured compared to 8.8% of White indi-
viduals [65]. The CDC reported that Black/African
American individuals received worse care than White
individuals for about 40% of health quality mea-
sures [65]. Many SES variables, socio-environmental
exposures, and medical care variables (access, uti-
lization, and discrimination) have been shown to
contribute to adverse health outcomes [41, 61, 66,
67]. In our opinion, neuroscientists should not only
adjust for these variables, but try to specifically
identify the factors that contribute to dementia
disparities in order to provide appropriate interven-
tions.
Examples are appearing in the literature that reveal
interactions between SES (particularly poverty) and
racial-ethnic factors [68–71], resulting in health dis-
parities that can, in turn, influence interpretations
of clinical and neuropathological associations. For
example, Glymour et al. found that childhood and
adult social conditions nearly entirely attenuated the
association between race and stroke risk in a study
population of 3,019 Blacks/African Americans and
17,642 Whites [72]. Waldstein et al., found signif-
icant interactions between race and SES composite
scores when predicting radiographically-detected
white matter lesions in a study population of 85
Blacks/African Americans and 62 White Americans
[68]. In a study of 1,019 Blacks/African Americans
and 1,438 White Americans, Yaffe et al. observed
that the incident dementia hazard ratio was greatly
reduced and no longer significant when SES was
added to the statistical model [71].
The results of these studies strongly support the
notion that genetically determinable mechanisms are
highly unlikely to entirely account for the higher
risk of dementia observed in Blacks/African Ameri-
cans compared to Whites. Therefore, it is necessary
to include SES variables in analyses when studying
dementia outcomes among Blacks/African Ameri-
cans. Failure to do so can result in misinterpretation
of data as to the root causes of dementia outcomes
within racial/ethnic groups. Notably, since 1994, NIH
guidelines have specifically called for researchers
to account for socioeconomic variables such as
occupation, education, and income among human
subjects [61].
The importance of autopsy-based (neuropatholog-
ical) data in AD and related dementias has also
become increasingly clear. For example, we high-
light that both dementia and type II diabetes (T2D)
are prevalent in Blacks/African Americans [72]. It
is notable that data from different research centers
have consistently reported that T2D is a risk factor for
AD-type dementia in the clinical (no autopsy) con-
text. By contrast, studies with a single added study
design element—an autopsy—have shown the oppo-
site result: T2D is not a risk factor for AD pathology
[73–75]. Instead, the autopsies reveal that the clin-
ical diagnosis of AD was not completely accurate,
and that T2D appears to exert its impact through a
different (potentially additive when comorbid) disor-
der: cerebrovascular disease characterized by small
and medium-sized blood vessel pathology [73]. Thus,
a more vulnerable population may be underserved
due to a clinical over-diagnosis of AD and an under-
appreciation of T2D-related cognitive impairment.
This is all the more topical since therapies aimed at
diabetes, blood pressure, and cholesterol may exert
an impact on cerebrovascular pathology, but not yet
AD itself.
Improving the representation of Blacks/African
Americans across research and clinical disciplines
will also enable improved research outcomes for
ADC research teams. According to the 2010 U.S.
Census Bureau report, Blacks/African Americans
make up 12.6% of the U.S. population [12]. However,
Blacks/African Americans make up only ∼3.6%
of biomedical research faculty, ∼4.1% of physi-
cians, and ∼5.9% of social scientist faculty within
the United States [76–78]. Several published stud-
ies have provided evidence that diversity of thought
and identity among scientists enhances the qual-
ity and output of research collaborations, which
makes for “better science” [79–81]. For example,
Campbell et al. reported that gender-heterogeneous
authorship teams received 34% more citations than
publications produced by gender-uniform authorship
teams [80].
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ADDRESSING THE PROBLEM:
CONSIDERATIONS FOR THE FIELD
It is appropriate that all populations within the
U.S. be represented in biomedical research stud-
ies. In formulating hypotheses and conceptualizing
study designs, the ultimate goal should be to improve
the health and well-being of the target population
[82]. In analyzing data within and across racial/
ethnic groups, we encourage neuroscientists to
strive for better science by shifting the paradigm
away from interpreting clinical/neuropathological
results based on the framework of biologic deter-
mination to understanding and incorporating both
biological and socio-environmental factors known
to affect health outcomes. Therefore, Blacks/African
Americans should be encouraged and included in
biomedical research for the sole purpose of improv-
ing their health outcomes, not simply to identify a
health disparity. With this paradigm shift in mind,
if one is going to embark on this field of inves-
tigation, it is necessary to understand and attempt
to account for the anthropological, psychological,
sociological, political, biological, and cultural asso-
ciations/causations attributing to health outcomes in
Blacks/African Americans. In Table 1, we have pro-
vided some points of considerations for scientists
embarking on this type of investigation. It is impor-
tant to note that Table 1 contents are not exhaustive
but a starting point for discussion.
Cultural competency when interpreting research
ﬁndings
Alongside adding new variables, we suggest that
scientists provide a rationale for their research ques-
tion and provide adequate discussion of research
findings (see Table 1). There should be justification
for studying “differences” between racial categories
[47, 83], information on categorization of study popu-
lation (e.g., skin color, self-report) [42], analyses and
discussions of socio-political factors that can con-
tribute to research findings [24, 42], and explanation
of the social, biological, and medical implications
of misinterpretation and misrepresentation of data
within their manuscript [47]. We encourage neurosci-
entists to solicit expert advice from anthropologists,
sociologists, psychologists, African American com-
munity leaders, and other individuals who can
provide contextual information on contributing fac-
tors to health outcomes. Ideally, these individuals
can serve as co-authors on clinical-neuropathological
manuscripts as suggested by Foster et al. who recom-
mends publishing in cross-discipline journals [47].
Table 1
Topical questions and recommendations for a study related to dementia in African Americans
Experimental Design:
i) How to choose and sample the African American population to study?
ii) What is the original hypothesis? If it involves studying “differences,” are the strata sufficiently large to allow for adequate power
for the detection of effect modification?
iii) What are potential confounders that must be included? How might they affect your hypothesis and experimental design?
iv) How do health disparities in marginalized groups affect participation in the study and potentially the outcomes? Because
“refusers” do not actually join the studies, how can potential differences or effects be estimated?
v) What is the justification for studying African Americans? What is the justification for excluding others groups (i.e., multi-racial
individuals)
vi) How does composition of the research team affect results?
vii) How does this study contribute to helping underserved populations?
Methods:
i) Establish population stratified sampling methods, possibly similar to those used in cancer registries
ii) Enroll numbers of African Americans to have sufficient power and precision to address the associations under consideration
iii) How was the comparison group(s) chosen? How was the reference group chosen?
iv) How were the individuals recruited in the study? Was there a difference in recruited strategies for individuals from different racial
categories?
v) How was data on racial category assigned and collected? (i.e., self-report)
Data collection:
i) SES variables (income, education, occupation, zip code, etc.)
ii) Exposures – social, other environmental
iii) Ancestry (i.e., country of birth, parent’s place of birth)
iv) Medical care (insurance status, primary care physician, utilization)
v) Impact of worker collecting the data on the results
Discussion:
i) Implication of results, consequences for misinterpretation
ii) Limitations of study (recruitment bias, autopsy bias, investigator bias)
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Recruitment of research participants
In terms of context-specific issues, there is a
lack of Black/African American representation in
clinical-neuropathological datasets. Many articles
have published goals and strategies for recruiting
Blacks/African Americans and other marginalized
groups into clinical studies—one major goal dis-
cussed in these articles is to build long-term
trust within the Black/African American community
[35, 40, 84]. Some recommendations for building
trust are as follows: 1) publicly acknowledging the
historical mistreatment of Blacks/African Americans
in biomedical research [24, 36, 83–85], 2) ade-
quately explaining the consent process [24, 36, 86],
and protections in place to prevent mistreatment, 3)
engaging in ongoing Q&A discussions with the com-
munity [24, 30, 40, 84, 85, 87, 88], and 4) creating
relationships that include patients, caregivers, health-
care providers, community leaders, researchers, and
study coordinators [89]. Secondly, ADCs should
actively enroll Blacks/African Americans, attach spe-
cific research questions, and perform power analyses
so that it can be ensured that comparisons among
individuals from different racial/ethnic groups will be
valid. At present, some research centers enroll a per-
centage consistent with the surrounding geographic
area (as the ADC) but that often just satisfies the
“inclusion table” and the group is too small to perform
any meaningful comparisons or analyses [90].
We believe that by implementing some of these
strategies, it can help to improve recruitment of
Blacks/Africans Americans across research institu-
tions. Moreover, it can help to provide neuroscientists
with appropriate sample sizes in order to understand
dementia progression in Blacks/African Americans.
In turn, it has the potential to lead to improved medi-
cal and societal solutions decreasing dementia within
the Black/African American population.
Data and brain tissue collection
In addition to building trust, we suggest that neu-
roscientists collect potentially confounding variables
to include in data analyses (see Table 1). Some of
these variables include income level, education, zip
code, nativity, health insurance status, income level,
primary care physician availability, and employment
status [42]. The addition of these variables would
aid neuroscientists in improving the understanding
and analysis of clinical-neuropathological findings in
Black/African Americans.
An additional point relates to the importance of
autopsy-based confirmation of medical diagnoses.
Autopsy-based neuropathological diagnoses are cen-
tral to AD research in general, but may be all the more
important in a historically underserved population
where clinical and social factors may track differently
than among the populations that have traditionally
been included in clinical studies. In order to improve
brain donation from Blacks/African Americans, we
suggest that recruitment strategies incorporate educa-
tion on the brain donation procedure and protection
of human subjects.
Recruiting and retaining a diverse biomedical
research workforce
It is important to have a culturally diverse group
of experts included in the research team [36, 84, 87].
One long-term strategy for ADCs can be to increase
African American representation among clinicians,
scientists, epidemiologists, biostatisticians, and study
coordinators to aid in experimental design and data
analysis of AD and related dementias within the
Black/African American population. Some strategies
include effective career mentoring [91, 92], address-
ing unconscious bias and stereotype threat [77], and
implementing pipeline and career development pro-
grams [93].
CONCLUSION
Studying AD and related dementias within the
Black/African American population is a complex task
due to the historical, cultural, and political factors
that play a role in Black/African American partic-
ipation in clinical studies. This commentary is not
an exhaustive list of challenges and considerations,
but, instead, aims to help move the discussion in the
right direction. Moreover, this information can be
applied to other underserved populations worldwide.
Dementia is a devastating and multi-faceted clinical
syndrome. We hope that dementia research centers
can improve their recruitment strategies, recognize
the subpopulation-specific challenges and opportu-
nities, and incorporate more of the relevant data.
Neuroscientists can create multi-disciplinary teams
focused on understanding dementia in Black/African
Americans and other marginalized groups, wary of
the fact that research has the potential to do harm as
well as good.
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